06 Mar / Civil Society Forum on drugs views and the EU Action Plan on Drugs
Report by the Civil Society Forum on Drugs working group on this EU Action Plan on Drugs.
The Civil Society Forum on Drugs (CSFD) is an expert group of the European Commission. It aims to contribute to the EU Plan on Drugs. Its members are selected by the Commission for a three-year mandate Particularly, based on their competences, knowledge and expertise.
Dianova is a member of the Civil Society Forum on Drugs in the EU CSFD since 2013. Along with other NGOs, a diversity of members of the Dianova international network have participated in the recent survey.
The goal: providing the ground work for the preparation of this report, sharing a wealth of experiences and practices. We’d like to thank them all for their participation. Furthermore, our representative from Dianova International was interviewed for the video “The EU Action Plan on Drugs: Civil Society Views”.
The Civil Society Forum on Drugs Report
The involvement of non-state actors on various levels of policy-making is one of the important issues of the European Union agenda. One of the manifestations of the EU efforts is to include civil society representation. Hence, in the work of various EU bodies appears the Civil Society Forum on Drugs. A space where European NGOs can work together and sit at the round table with EU representatives.
The Civil Society Forum on Drugs (CSFD) is an expert group of the European Commission. The selection of its members by the Commission is for a three-year mandate based on their competences, knowledge and expertise.
One of its thematic working groups is concerned with the EU drug strategies and action plans.
The EU Drug Strategy Plan is a document “providing the overarching political framework and priorities for EU drugs policy identified by Member States and EU institutions” (European Council, 2012). Thus, setting the general directions of the field development.
On one hand, it’s grounds are the EU values and principles on the one hand. And on the other the international agreements. As an illustration, the United Nations conventions on psychoactive substances. The strategy constitutes a “base” to guide Action Plans on Drugs. In brief, documents encompassing 4-year periods and enlisting more specific actions and measures to be undertaken.
Know more about the Civil Society Forum on Drugs and the EU Plan on drugs
The adoption of the current EU Drug Strategy was for 2013-20. And its Action Plans for 2013-16 and 2017-20, respectively. The documents focus on few areas of drug policy. Namely, Drug demand reduction, drug supply reduction, coordination, international cooperation, information, research, monitoring and evaluation.
Important to realize their support for solutions that are evidence-based and strongly embedded in human rights and public health approach to the drug problem. As such, they are by all means the most progressive EU documents of this type so far. However, EU strategy and action plans are documents of recommendation character only. In other words, they are not legally binding.
Therefore, each and every EU member state has a full discretion over its drug policy (unless restricted by ratified international treaties). To clarify, the degree of following EU recommendation and reflecting them in domestic policies and laws can vary significantly from country to country.
This is the reason of the involvement of CSFD’s Working Group on the EU Drug Strategy and Action plan in the evaluation of the EU drug strategy (2013-20). Both on the previous Action Plan on Drugs and the preparation of the new Action Plan (2017-20). The Forum has also decided to contribute to the monitoring and evaluation of the current Action Plan (2017-20).
Consequently, we conducted a research among European NGOs working in the field. The goal was to assess their perspectives and views on how relevant actions of the document are implemented in their countries.
This report consists of five main parts.
> First, we will describe the methodology and data sources of this inquiry.
> Second, we will discuss the services accessibility and quality in general.
> Third, we will provide a comparative analysis of the European regions included in the study.
> Fourth, we will look more closely at services accessibility and quality in the context of few specific and vulnerable populations. Specifically, youth, elderly, women, ethnic minorities/immigrants and inmates.
> Finally, we will present barriers to the effective implementation of the EU Action Plan and draw a set of recommendations for various stakeholders.
Report drafted by courtesy of Dianova International, member of the Civil Society Forum on Drugs
Iga Kender-Jeziorska (Youth Organisations for Drug Action)
Péter Sárosi (Rights Reporter Foundation)